[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 42 of about 42
1. Haro Estarriol M, Baldo Padró X, Rubio Goday M, Sebastián Quetglas F, Viñas Villaró G, Bernadó Turmo L: [Primary pulmonary synovial sarcoma: a report and diagnosis of 2 cases]. Arch Bronconeumol; 2003 Mar;39(3):136-8
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary pulmonary synovial sarcoma: a report and diagnosis of 2 cases].
  • [Transliterated title] Sarcoma sinovial pulmonar primario. Presentación y diagnóstico de dos casos.
  • Synovial sarcoma is an extremely rare primary pulmonary tumor whose description is based on a limited number of cases.
  • One patient was initially treated surgically, and a later recurrence was controlled by combined chemotherapy and a second operation after three years of monitoring.
  • In the second case, surgery was imperative to treat massive hemoptysis and was followed by combined chemotherapy after diagnosis of lesions consistent with extrapulmonary metastasis.
  • [MeSH-major] Lung Neoplasms. Sarcoma, Synovial
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bronchoscopy. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery. Radiography, Thoracic. Reoperation. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12622974.001).
  • [ISSN] 0300-2896
  • [Journal-full-title] Archivos de bronconeumología
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


2. Suárez Antelo J, Rodríguez García C, Montero Martínez C, Verea Hernando H: [Pulmonary Ewing sarcoma/primitive neuroectodermal tumor: a case report and a review of the literature]. Arch Bronconeumol; 2010 Jan;46(1):44-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary Ewing sarcoma/primitive neuroectodermal tumor: a case report and a review of the literature].
  • [Transliterated title] Sarcoma de Ewing pulmonar/tumor neuroectodérmico primitivo (PNET): aportación de un caso y revisión de la bibliografía.
  • The most common intrathoracic variants are synovial sarcoma, angiosarcoma, leiomyosarcoma, rhabdomyosarcoma, and sarcomatoid mesothelioma.
  • Although thoracic Ewing sarcoma/primitive neuroectodermal tumor (PNET) usually develops on the chest wall, there have been reports of primary Ewing sarcoma/PNET of the lung.
  • We present the case of a 22-year-old woman with Ewing sarcoma/PNET diagnosed following histologic, immunohistochemical, and in situ hybridization studies of a bronchial biopsy specimen.
  • The patient was started on a chemotherapy regimen of vincristine, actinomycin, cyclophosphamide, doxorubicin, ifosfamide, and etoposide and responded well.
  • [MeSH-major] Lung Neoplasms. Neuroectodermal Tumors, Primitive. Sarcoma, Ewing

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 SEPAR. Published by Elsevier Espana. All rights reserved.
  • (PMID = 19656607.001).
  • [ISSN] 1579-2129
  • [Journal-full-title] Archivos de bronconeumología
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 13
  •  go-up   go-down


3. Park SJ, Kim HK, Kim CK, Park SK, Go ES, Kim ME, Hong DS: A case of renal synovial sarcoma: complete remission was induced by chemotherapy with doxorubicin and ifosfamide. Korean J Intern Med; 2004 Mar;19(1):62-5
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of renal synovial sarcoma: complete remission was induced by chemotherapy with doxorubicin and ifosfamide.
  • We experienced a case of primary renal synovial sarcoma in a 32 year-old woman.
  • On radiologic examination, a 12 x 10 cm-sized soft tissue mass was detected on the left kidney.
  • The tumor had histologic and immunophenotypic features that were consistent with spindle cell type monophasic synovial sarcoma.
  • Four months after complete resection of the tumor, a unilateral hematogenous metastasis developed in the lung.
  • She was treated with combined chemotherapy of doxorubicin and ifosfamide every four weeks, and complete remission was achieved.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Sarcoma, Synovial / drug therapy. Sarcoma, Synovial / secondary

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15053047.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  • [Other-IDs] NLM/ PMC4531551
  •  go-up   go-down


Advertisement
4. Kataria T, Janardhan N, Abhishek A, Sharan GK, Mitra S: Pulmonary metastasis from renal synovial sarcoma treated by stereotactic body radiotherapy: a case report and review of the literature. J Cancer Res Ther; 2010 Jan-Mar;6(1):75-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary metastasis from renal synovial sarcoma treated by stereotactic body radiotherapy: a case report and review of the literature.
  • Primary synovial sarcoma of kidney is an uncommon neoplasm, metastasizing most commonly to lung.
  • Surgery and/or palliative chemotherapy for pulmonary metastases is commonly used to improve tumor control and survival.
  • Furthermore, with advancement of imaging techniques, immobilization techniques, tumor-tracking techniques, and treatment planning and delivery system, SBRT can now be alternatively employed for the treatment of pulmonary metastasis as a comparable substitute to surgical resection.
  • [MeSH-major] Kidney Neoplasms / pathology. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Radiosurgery. Sarcoma, Synovial / pathology. Sarcoma, Synovial / surgery

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479551.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 6
  •  go-up   go-down


5. Krieghoff B, Skuballa A, Leonhardt P, Mohr FW, Wittekind C, Bossert T, Achatzy R: [Primary synovial sarcoma of the lung - a rare tumor]. Zentralbl Chir; 2002 Aug;127(8):716-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary synovial sarcoma of the lung - a rare tumor].
  • We present a 26 year old patient with a primary malignant synovial sarcoma of the lung that was observed for more than one year by a general practitioner and a pulmologist.
  • In the postoperative course the patient underwent chemo-therapy, 6 cycles adriablastine/ifosfamid.
  • The patient refused further radio- or chemotherapy and died 14 months after the operation.
  • Because of the small number of cases therapeutic strategy conceptions do not exist.
  • [MeSH-major] Lung Neoplasms / surgery. Sarcoma, Synovial / surgery
  • [MeSH-minor] Adult. Bronchoscopy. Diagnosis, Differential. Diagnostic Imaging. Humans. Lung / pathology. Male. Neoplasm Staging. Pneumonectomy

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12200737.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Henninger B, Freund M, Zelger B, Putzer D, Bonatti H, Müller L, Fiegl M, Geltner C: Primary mediastinal synovial sarcoma: a case report and review of the literature. Cases J; 2009;2:6948

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal synovial sarcoma: a case report and review of the literature.
  • Primary mediastinal synovial sarcoma is a rare malignancy with only a few cases reported so far.
  • A 56-year-old woman was admitted to our hospital for an investigation of a nodule in the left middle lung on chest radiography.
  • Computed tomography revealed a mediastinal mass first described as a solitary fibrous tumor.
  • The diagnosis of synovial sarcoma was established by computed tomography-guided percutaneous needle biopsy.
  • The mass was surgically resected; pathological and immunohistochemical analyses confirmed the diagnosis of a monophasic spindle cell synovial sarcoma probably originating from phrenic nerve.
  • The patient received adjuvant chemotherapy and radiation and is free of recurrence after a follow up of 16 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comput Assist Tomogr. 2008 Mar-Apr;32(2):238-41 [18379309.001]
  • [Cites] J Clin Oncol. 2000 Nov 15;18(22):3794-803 [11078492.001]
  • [Cites] Ulster Med J. 2007 May;76(2):109-11 [17476827.001]
  • [Cites] Histopathology. 2006 Jan;48(1):3-12 [16359532.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):569-78 [15832079.001]
  • [Cites] J Surg Oncol. 1999 Mar;70(3):194-8 [10102352.001]
  • [Cites] Am J Surg Pathol. 1989 Jun;13(6):490-9 [2471414.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):627-34 [15274077.001]
  • [Cites] Surg Today. 2004;34(6):521-4 [15170549.001]
  • [Cites] CA Cancer J Clin. 2004 Mar-Apr;54(2):94-109 [15061599.001]
  • [Cites] Clin Orthop Relat Res. 2004 Feb;(419):155-61 [15021147.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 2002 Feb;65(2):83-5 [12014364.001]
  • [Cites] Radiographics. 2002 May-Jun;22(3):621-37 [12006691.001]
  • [Cites] Ann Thorac Surg. 2002 Feb;73(2):628-30 [11845884.001]
  • [Cites] Niger J Med. 2007 Apr-Jun;16(2):94-101 [17694759.001]
  • (PMID = 19918499.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2769329
  •  go-up   go-down


7. Takeda K, Kunisada T, Miyazawa S, Nakae Y, Ozaki T: Photodynamic therapy with ATX-S10.Na(II) inhibits synovial sarcoma cell growth. Clin Orthop Relat Res; 2008 Jul;466(7):1726-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy with ATX-S10.Na(II) inhibits synovial sarcoma cell growth.
  • Photodynamic therapy (PDT) is an effective cancer treatment modality that allows selective destruction of malignant tumor cells.
  • We asked whether PDT could inhibit in vivo and in vitro growth of synovial sarcoma cells.
  • We analyzed PDT using ATX-S10.Na(II) and a diode laser for a synovial sarcoma cell line (SYO-1).
  • Photodynamic therapy with ATX-S10.Na(II) showed an in vitro cytotoxic effect on the cultured SYO-1 cells.
  • The in vitro effect of PDT depended on the treatment concentration of ATX-S10.Na(II) and the laser dose of irradiation.
  • ATX-S10.Na(II) was detected in the tumor tissue specimens that were excised from nude mice bearing SYO-1 within 6 hours after intravenous injection, but it was eliminated from the tumor 12 hours after injection.
  • Photodynamic therapy suppressed the tumor growth of nude mice bearing SYO-1, and high-dose irradiation induced no viable tumor cells in histologic specimens.
  • Photodynamic therapy performed after marginal resection of the tumor of nude mice bearing SYO-1 reduced the rate of local recurrence of the tumor.
  • Our results suggest PDT using ATX-S10.Na(II) and laser irradiation may be a potentially useful treatment for synovial sarcoma, especially to reduce the surgical margin and preserve critical anatomic structures adjacent to the tumor.
  • [MeSH-major] Photochemotherapy. Sarcoma, Synovial / drug therapy
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation / radiation effects. Disease Models, Animal. Mice. Mice, Nude. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use. Xenograft Model Antitumor Assays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4289-94 [12154031.001]
  • [Cites] Clin Dermatol. 2001 May-Jun;19(3):328-38 [11479045.001]
  • [Cites] Int J Colorectal Dis. 2003 May;18(3):239-47 [12673490.001]
  • [Cites] Lasers Med Sci. 2003;18(3):134-8 [14505196.001]
  • [Cites] Lung Cancer. 2003 Oct;42(1):103-11 [14512194.001]
  • [Cites] Cancer Lett. 2004 Feb 10;204(1):105-13 [14744540.001]
  • [Cites] Br J Cancer. 2004 Aug 2;91(3):441-6 [15238981.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2004 Oct;20(5):257-65 [15379877.001]
  • [Cites] Jpn J Cancer Res. 1992 Feb;83(2):226-31 [1556004.001]
  • [Cites] Photochem Photobiol. 1992 Jan;55(1):145-57 [1603846.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1269-75 [8315424.001]
  • [Cites] Br J Urol. 1996 May;77(5):667-71 [8689107.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):197-203 [9440743.001]
  • [Cites] J Clin Laser Med Surg. 1996 Oct;14(5):343-8 [9612202.001]
  • [Cites] J Natl Cancer Inst. 1998 Jun 17;90(12):889-905 [9637138.001]
  • [Cites] Anticancer Drugs. 1998 Jul;9(6):539-43 [9877242.001]
  • [Cites] Br J Cancer. 1999 Apr;79(11-12):1702-8 [10206280.001]
  • [Cites] Lasers Surg Med. 1999;24(3):194-201 [10229150.001]
  • [Cites] Lasers Surg Med. 1999;24(3):209-22 [10229152.001]
  • [Cites] Arch Dermatol. 2005 Jan;141(1):60-7 [15655143.001]
  • [Cites] Arch Dermatol Res. 2005 Apr;296(10):496-502 [15759135.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2B):1225-35 [15865070.001]
  • [Cites] BJU Int. 2005 Jun;95(9):1206-10 [15892802.001]
  • [Cites] Scand J Gastroenterol. 2005 Jul;40(7):750-8 [16118910.001]
  • [Cites] Int J Oncol. 2005 Nov;27(5):1207-13 [16211214.001]
  • [Cites] Lasers Surg Med. 2006 Jun;38(5):435-8 [16470845.001]
  • [Cites] Jpn J Cancer Res. 2000 Apr;91(4):439-45 [10804293.001]
  • [Cites] J Dermatol. 2000 May;27(5):294-306 [10875195.001]
  • [Cites] Jpn J Cancer Res. 2000 Jul;91(7):753-9 [10920284.001]
  • [Cites] Jpn J Cancer Res. 2000 Aug;91(8):845-52 [10965027.001]
  • [Cites] Oncology. 2000 Aug;59(2):174-80 [10971178.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1238-47 [11230464.001]
  • [Cites] Urology. 2003 Feb;61(2):338-41 [12597942.001]
  • (PMID = 18465181.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ATX-S10; 0 / Photosensitizing Agents; 0 / Porphyrins
  • [Other-IDs] NLM/ PMC2505266
  •  go-up   go-down


8. Bilgic B, Mete O, Oztürk SA, Demiryont M, Keles N, Basaran M: Synovial sarcoma: a rare tumor of larynx. Pathol Oncol Res; 2003;9(4):242-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synovial sarcoma: a rare tumor of larynx.
  • Synovial sarcoma is a soft tissue sarcoma of unknown histogenesis and occurs predominantly in the lower extremities of young adults.
  • Incisional biopsy and the hemilaryngectomy material revealed a biphasic synovial sarcoma.
  • Six months later lung metastases was discovered on thoracic CT.
  • The patient received chemotherapy for 6 courses.
  • The metastases responded well to chemotherapy and the patient is now alive without tumor on radiological and clinical examination after 3.5 years of follow-up.
  • [MeSH-major] Laryngeal Neoplasms / pathology. Sarcoma, Synovial / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Humans. Immunohistochemistry. Laryngectomy. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Radiotherapy

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1984 Sep;94(9):1158-61 [6088920.001]
  • [Cites] Med Pediatr Oncol. 1994;23(1):64-8 [8177148.001]
  • [Cites] Laryngorhinootologie. 1994 Aug;73(8):442-4 [7945664.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2001 Jun;21(3):192-7 [11677847.001]
  • [Cites] Acta Orthop Scand Suppl. 2000 Apr;291:1-28 [10862210.001]
  • [Cites] Arch Otolaryngol. 1980 Jan;106(1):8-12 [6928099.001]
  • [Cites] Arch Otolaryngol. 1975 Oct;101(10):633-6 [169770.001]
  • [Cites] Br J Cancer. 1999 Aug;80(11):1809-14 [10468301.001]
  • [Cites] Trans Sect Otolaryngol Am Acad Ophthalmol Otolaryngol. 1975 Sep-Oct;80(5):448-51 [173067.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1998 Dec;107(12):1080-5 [9865642.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 1991;53(2):116-9 [1849243.001]
  • [Cites] Head Neck. 1989 Jan-Feb;11(1):76-80 [2537802.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1997;254(8):357-66 [9332890.001]
  • [Cites] Vestn Otorinolaringol. 1985 Mar-Apr;(2):61-2 [2988174.001]
  • [Cites] Ann Pathol. 2001 Feb;21(1):71-5 [11223565.001]
  • [Cites] Virchows Arch. 1999 Oct;435(4):407-12 [10526004.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 1983;100(1):61-5 [6303187.001]
  • (PMID = 14688831.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


9. Mirzoyan M, Muslimani A, Setrakian S, Swedeh M, Daw HA: Primary pleuropulmonary synovial sarcoma. Clin Lung Cancer; 2008 Sep;9(5):257-61
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pleuropulmonary synovial sarcoma.
  • Pleuropulmonary synovial sarcoma (PPSS) is increasingly recognized as a subtype of sarcoma because of the recent identification of a distinctive chromosomal translocation specific to synovial sarcoma.
  • Soft-tissue synovial sarcoma is far more common than PPSS and typically develops in para-articular locations of the extremities, affects young and middle-aged adults, with no difference in distribution between the sexes, and has well-documented radiologic manifestations.
  • Pleuropulmonary synovial sarcoma can arise in the chest wall, heart, mediastinum, pleura, or lung, and it shares patient demographics and several imaging features with its soft-tissue counterpart.
  • On chest radiographs, PPSS typically appears as a sharply marginated mass with uniform opacity, based in the pleura or in the lung, and often accompanied by an ipsilateral pleural effusion.
  • Magnetic resonance imaging provides superior demonstration of nodular soft tissue and multilocular fluid-filled internal components of PPSS, in addition to peripheral rim enhancement after the intravenous administration of a gadoliniumbased contrast material such as gadopentetate dimeglumine.
  • Current treatment consists of surgical resection followed by chemotherapy, radiation therapy, or both.
  • [MeSH-major] Lung Neoplasms / pathology. Pleural Neoplasms / pathology. Sarcoma, Synovial / pathology

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824448.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 51
  •  go-up   go-down


10. Frazier AA, Franks TJ, Pugatch RD, Galvin JR: From the archives of the AFIP: Pleuropulmonary synovial sarcoma. Radiographics; 2006 May-Jun;26(3):923-40
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From the archives of the AFIP: Pleuropulmonary synovial sarcoma.
  • Pleuropulmonary synovial sarcoma (PPSS) is increasingly recognized as a subtype of sarcoma because of the recent identification of a distinctive chromosomal translocation specific to synovial sarcoma.
  • Soft-tissue synovial sarcoma is far more common than PPSS and typically develops in para-articular locations of the extremities; affects young and middle-aged adults, with no difference in distribution between the sexes; and has well-documented radiologic manifestations.
  • PPSS may arise in the chest wall, heart, mediastinum, pleura, or lung, and it shares patient demographics and several imaging features with its soft-tissue counterpart.
  • On chest radiographs, PPSS typically appears as a sharply marginated mass with uniform opacity, based either in the pleura or in the lung, and often accompanied by an ipsilateral pleural effusion.
  • Magnetic resonance imaging provides superior demonstration of nodular soft tissue and multilocular fluid-filled internal components of PPSS, in addition to peripheral rim enhancement after the intravenous administration of a gadolinium-based contrast material such as gadopentetate dimeglumine.
  • Current treatment consists of surgical resection followed by chemotherapy, radiation therapy, or both.
  • [MeSH-major] Image Enhancement / methods. Lung Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Pleural Neoplasms / diagnosis. Sarcoma, Synovial / diagnosis

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702463.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 47
  •  go-up   go-down


11. Stage AC, Pollock RE, Matin SF: Bilateral metastatic renal synovial sarcoma. Urology; 2005 Feb;65(2):389
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral metastatic renal synovial sarcoma.
  • Synovial sarcoma is a malignant soft-tissue neoplasm, usually arising in close association with the joints and generally carrying a poor prognosis.
  • We describe the first report of bilateral renal metastases from synovial sarcoma in a long-term survivor.
  • Treatment consisted of systemic therapy with bilateral partial nephrectomies.
  • [MeSH-major] Forearm. Kidney Neoplasms / secondary. Sarcoma, Synovial / secondary. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Amputation. Antineoplastic Agents, Alkylating / therapeutic use. Combined Modality Therapy. Female. Humans. Ifosfamide / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Middle Aged. Nephrectomy / methods

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15708068.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 3
  •  go-up   go-down


12. Provenzano SC, Con R, Jones OD, Grant PW: Synovial sarcoma of the heart. Heart Lung Circ; 2006 Aug;15(4):278-9
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synovial sarcoma of the heart.
  • We report a case of synovial sarcoma of the heart in a 14-year-old boy, who presented with signs of mild generalized illness and rapidly progressed to haemodynamic collapse.
  • He was considered to have incomplete resection due to extensive adhesions to the atrioventricular junction, and was offered chemotherapy.
  • [MeSH-major] Heart Neoplasms / diagnosis. Sarcoma, Synovial / diagnosis. Tricuspid Valve / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Atrioventricular Node / pathology. Combined Modality Therapy. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16600683.001).
  • [ISSN] 1443-9506
  • [Journal-full-title] Heart, lung & circulation
  • [ISO-abbreviation] Heart Lung Circ
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


13. Iwata T, Nishiyama N, Izumi N, Tsukioka T, Suehiro S: Metastatic monophasic synovial sarcoma of the pleura. Ann Thorac Cardiovasc Surg; 2007 Aug;13(4):258-61
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic monophasic synovial sarcoma of the pleura.
  • Pleural metastasis of synovial sarcoma that originally developed in the soft tissue is a very rare entity.
  • An asymptomatic 25-year-old female, with a history of a resected synovial sarcoma in her left brachial muscle and pulmonary metastasectomy of the right lung, presented a small nodule in the periphery of the left lung on a routine chest-computed tomography.
  • The tumor was removed by partial resection of the lung.
  • The mass lay in the pleura and did not seem to invade the lung parenchyma macroscopically.
  • Intraoperative frozen sectioning evidenced metastatic synovial sarcoma.
  • Many small patchy red lesions were also found on the visceral pleura of the lung and parietal pleura of the diaphragm.
  • We diagnosed unresectable pleural metastases of synovial sarcoma and finished the operation after sampling another pulmonary pleural lesion.
  • The patient then underwent ifomide-based chemotherapy and survived for 3 years after her initial surgery.
  • Postoperative histopathological examination revealed a solid and bundle-like proliferation of a short spindle cell tumor with a monophasic pattern, which was diagnosed as a metastatic pleural synovial sarcoma.
  • [MeSH-major] Muscle Neoplasms / pathology. Pleural Neoplasms / secondary. Sarcoma, Synovial / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17717503.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Caliandro R, Terrier P, Regnard JF, De Montpréville V, Ruffié P: [Primary biphasic synovial sarcoma of the pleura]. Rev Mal Respir; 2000 Apr;17(2):498-502
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary biphasic synovial sarcoma of the pleura].
  • However, the atypical clinical course, the early development of lung metastases and a new reading of histologic documents led to the diagnosis of primary pleural synovial sarcoma.
  • Because the efficacy of chemotherapy and/or radiotherapy is poor, surgery remains the basis of treatment, whenever possible.
  • Evolution is mainly intra-thoracic, with multiple local recurrences and lung metastases.
  • [MeSH-major] Pleural Neoplasms / pathology. Sarcoma, Synovial / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Immunohistochemistry. Lung Neoplasms / secondary. Male. Mesothelioma / pathology. Neoplasm Recurrence, Local / pathology. Prognosis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10859770.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] FRANCE
  • [Number-of-references] 14
  •  go-up   go-down


15. Schoeffski P, Cerbone L, Wolter P, Stas M, Dumez H, Clement P, Wildiers H, Paridaens R, van Oosterom AT: Administration of 24-hour intravenous infusions of trabectedin every 3 weeks in ambulatory patients with mesenchymal tumors via disposable elastomeric pumps. J Clin Oncol; 2009 May 20;27(15_suppl):e13530

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e13530 Background: Patients (pts) with sarcoma whose disease progresses after standard chemotherapy have poor outcome.
  • It is administered as 24-h i.v. infusion q3w with steroid co-medication.
  • To overcome the inconvenience of hospitalization for drug delivery TRA is now given in Leuven via disposable elastomeric pumps, which facilitate ambulatory treatment and are compatible with the drug.
  • MATERIAL AND METHODS: Heavily pre-treated pts with sarcoma were offered chemotherapy with TRA 1.5 mg/m<sup>2</sup> as 24-h i.v. infusion via port catheter, either during hospitalization using electronic pumps or as outpatients using the Baxter LV10 disposable pump (drug dissolved in 267 ml NaCl 0.9%).
  • Co-medication consisted of antiemetics and dexamethasone 2x4 mg days -1,1,2,3.
  • RESULTS: Between 09/07-12/08 28 pts were treated, and 21 (75%) elected outpatient therapy (9 F, 12 M, med. age 49 yrs, range 19-68).
  • Common diagnoses included leiomyo- (5), lipo- (4), synovial (2) and myxofibrosarcomas.
  • They had local relapse (2), distant metastasis (12) or both (7) when starting TRA, 19 had received previous chemotherapy with a med. number of 2 prior lines (range, 0-5).
  • Grade 3/4 (CTC) AEs were limited to one case each of hemorrhage and lung embolism, other AEs were in line with published TRA experience.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961332.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Mita AC, Sankhala K, Sarantopoulos J, Carmona J, Okuno S, Goel S, Chugh R, Coffey MC, Mettinger K, Mita MM: A phase II study of intravenous (IV) wild-type reovirus (Reolysin) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung. J Clin Oncol; 2009 May 20;27(15_suppl):10524

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of intravenous (IV) wild-type reovirus (Reolysin) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung.
  • In vitro and in vivo studies with Reolysin in sarcoma cell lines revealed significant antitumor activity.
  • METHODS: This phase II open-label, single agent study was designed to characterize the efficacy and safety of Reolysin given IV every 28 days in patients (pts) with bone or soft tissue sarcoma with lung metastasis using a Simon two-stage design.
  • 38 pts received prior chemotherapy, radiotherapy, biological agents or combinations for their metastatic disease, 15 pts received more than 3 chemotherapy regimens.
  • The sarcoma subtypes included: synovial sarcoma (13 pts), osteosarcoma (7 pts), leiomyosarcoma (7 pts), MFH (5 pts), Ewing/PNET (1 pt), chordoma (1 pt), others (9 pts).
  • CONCLUSIONS: Utilization of single agent reovirus for treatment of sarcoma is a novel and unique therapeutic approach to date.
  • Reolysin is well tolerated and shows promise for the treatment of metastatic sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963913.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Ruka W, Rutkowski P, Falkowski S, Morysinski T, Nowecki ZI: Aggressive combined treatment of synovial sarcoma patients (pts) without distant metastases - single-center experience. J Clin Oncol; 2004 Jul 15;22(14_suppl):9018

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive combined treatment of synovial sarcoma patients (pts) without distant metastases - single-center experience.
  • : 9018 Background: Synovial sarcoma (SS) is a common type of high-grade soft tissue sarcoma (STS) with significant sensitivity to chemotherapy and poor prognosis (ASCO 1994, abst. 1645).
  • The aim of this single-center study was to analyze the results of intensive chemo- and radiotherapy treatment in pts with nonmetastastic (M0) SS.
  • METHODS: One hundred consecutive M0 SS pts (median age 32 years, range: 15-70; 23 pts had primary tumors and 77 pts - recurrences or scars after non-radical excision, 40% of tumors >5 cm) treated between 1995 and 2003 received chemotherapy (2 cycles of high-dose ifosfamide at dose of 11.9g/m<sup>2</sup>/7 days) and radiotherapy (20Gy over 5 days - 4Gy/fractions; fields contained the tumor - primary, recurrent or scar with drain sites and margins ≥ 5 cm) before surgical resection, followed by 4 cycles of postoperative multiagent chemotherapy (2 of ifosfamide - 11.9g/m<sup>2</sup>/7days and 2 of doxorubicin - 60mg/m<sup>2</sup> and cisplatin - 120mg/m<sup>2</sup>).
  • Median follow-up time was 21 months.
  • RESULTS: 92 pts received complete treatment, grade 3 and 4 toxicity (CTC 2.0) was observed in 27% of pts.
  • There were 15 deaths due to disease progression and 31 recurrences of the disease (primary: mostly - lung metastases in 18 pts and local recurrences in 7 pts).
  • CONCLUSIONS: The encouraging results of intensive combined treatment of pts with localized SS indicate the 5-year survival rate of about 80% in this highly malignant type of STS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013671.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Hasegawa T, Yokoyama R, Matsuno Y, Shimoda T, Hirohashi S: Prognostic significance of histologic grade and nuclear expression of beta-catenin in synovial sarcoma. Hum Pathol; 2001 Mar;32(3):257-63
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of histologic grade and nuclear expression of beta-catenin in synovial sarcoma.
  • Synovial sarcoma, which has a wide spectrum of biologic behavior, warrants accurate grading to assess the patient's prognosis.
  • We studied the clinicopathologic and immunohistochemical features of 44 cases of synovial sarcoma in patients treated primarily or secondarily at the National Cancer Center, Tokyo, to identify independent prognostic factors.
  • There were local recurrences in 16 patients (36%), and 25 (57%) developed metastases, primarily to the lungs.
  • Variables associated with an adverse outcome included tumor size > 6.7 cm; initial treatment outside the National Cancer Center; poorly differentiated subtype; high nuclear atypia; mitosis count > 27/10 high-power fields; tumor necrosis; absence of stromal calcification; nuclear expression of beta-catenin, which was found in 25 cases (57%); Ki-67 (MIB-1) index > 27%; and histologic grade 3.
  • Nuclear accumulation of beta-catenin as a cell-signaling event may play an important role in the progression of synovial sarcoma and therefore might be predictive of short survival.
  • Most variables were correlated with lung metastasis and histologic grade.
  • High-grade synovial sarcoma assessed by a histologic grading system based on the proliferative activity of the neoplastic cells can be viewed as high risk with the patients most likely to die of disease within 10 years after surgery and in need of improved chemotherapy.
  • [MeSH-major] Cell Nucleus / chemistry. Cytoskeletal Proteins / analysis. Sarcoma, Synovial / pathology. Trans-Activators
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Lung Neoplasms / secondary. Male. Middle Aged. Mitosis. Necrosis. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prognosis. Survival Rate. beta Catenin

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company
  • (PMID = 11274633.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / Ki-67 Antigen; 0 / Trans-Activators; 0 / beta Catenin
  •  go-up   go-down


19. Ulmer C, Kettelhack C, Tunn PU, Reichardt P, Hohenberger P, Schlag PM: [Synovial sarcoma of the extremities. Results of surgical and multimodal therapy]. Chirurg; 2003 Apr;74(4):370-4
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synovial sarcoma of the extremities. Results of surgical and multimodal therapy].
  • [Transliterated title] Synovialsarkome der Extremitäten. Ergebnisse chirurgischer und multimodaler Therapie.
  • BACKGROUND: Synovial sarcoma is a rare tumor frequently occurring in adolescents and young adults.
  • The preferred location, at the distal parts of the extremities, and the high incidence of distant metastases represent major challenges for treatment.
  • The purpose of this study is to analyze the indications for surgery in the context of a multimodal therapy.
  • PATIENTS AND METHODS: Between October 1992 and December 2000, 41 patients were treated surgically for synovial sarcoma of the extremities.
  • At the time of presentation, seven patients had distant metastases; three located in the lung and four in lymph nodes.
  • RESULTS: Due to a locally unresectable tumor or synchronous distant metastases, 28 patients (68%) underwent preoperative systemic chemotherapy (n=9) or isolated limb perfusion (n=18) or both (n=1).
  • Of the 12 patients (29%) who required amputation, 85% had a distal tumor.
  • Sixteen patients received additional postoperative radio- and/or chemotherapy.
  • After a median follow-up of 30 months, only two patients (7%) had developed a local recurrence, while seven patients (20%) suffered from new, distant metastases.
  • CONCLUSION: With a combined modality treatment, it is possible to achieve excellent local control rates and long-term survival in patients with synovial sarcoma of the extremities.
  • Neoadjuvant treatment can enable limb-sparing surgery in most patients, even if the tumors are located in anatomically difficult areas.
  • [MeSH-major] Extremities / surgery. Sarcoma, Synovial / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Amputation / mortality. Chemotherapy, Adjuvant. Child. Combined Modality Therapy / methods. Combined Modality Therapy / mortality. Female. Follow-Up Studies. Humans. Limb Salvage / mortality. Lung Neoplasms / mortality. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Lymphatic Metastasis. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Neoplastic Cells, Circulating. Radiotherapy, Adjuvant. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12719879.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Mitsuhashi A, Nagai Y, Suzuka K, Yamazawa K, Nojima T, Nikaido T, Ishikura H, Matsui H, Shozu M: Primary synovial sarcoma in fallopian tube: case report and literature review. Int J Gynecol Pathol; 2007 Jan;26(1):34-7
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary synovial sarcoma in fallopian tube: case report and literature review.
  • Synovial sarcoma, a malignant mesenchymal neoplasm, occurs mostly near the joints of the extremities and occasionally outside the joint such as lung.
  • We report a case of soft tissue sarcoma arising in the fallopian tube origin that showed characteristic pathological appearance of biphasic synovial sarcoma.
  • Molecular analysis detected a fusion gene transcript of synovial sarcoma translocation (SYT) gene from chromosome 18 and synovial sarcoma X chromosome breakpoint 1 (SSX1) gene, which is believed to pathognomonic for synovial sarcoma of joint origin.
  • Recurrent abdominal tumor, observed at 12 month after the initial surgery and following chemotherapy using doxorubicin, cisplatin and ifosfamide, partially responded to chemotherapy using paclitaxel and carboplatin and, then, optimal surgery was performed.
  • This is the first report of a synovial sarcoma arising in the fallopian tube.
  • [MeSH-major] Fallopian Tube Neoplasms / pathology. Sarcoma, Synovial / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197895.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / SYT-SSX fusion protein
  • [Number-of-references] 12
  •  go-up   go-down


21. Haight J, Caprioli R, Esposito M, Macias A, Lucchese M, Davis E: Synovial sarcoma involving the calcaneus and plantar compartment of the foot: a case report. J Foot Ankle Surg; 2010 Jul-Aug;49(4):398.e1-4
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synovial sarcoma involving the calcaneus and plantar compartment of the foot: a case report.
  • Synovial sarcoma arising in the foot is a rare finding.
  • We report a 64-year-old female with synovial sarcoma involving the calcaneus and central plantar compartment.
  • The patient presented with a 2-year history of painful heel with soft tissue mass presentation 21 months after initial pain.
  • We performed an incisional biopsy with frozen section; histopathology was consistent with synovial sarcoma.
  • [MeSH-major] Calcaneus / pathology. Sarcoma, Synovial / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Analgesics / administration & dosage. Biopsy. Female. Foot. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American College of Foot and Ankle Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20537566.001).
  • [ISSN] 1542-2224
  • [Journal-full-title] The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons
  • [ISO-abbreviation] J Foot Ankle Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics
  •  go-up   go-down


22. Kijima Y, Yoshinaka H, Higashi M, Yokouchi M, Komiya S, Hisaoka M, Aikou T: Metastatic breast tumor arising from synovial sarcoma: report of a case. Surg Today; 2007;37(3):230-3
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic breast tumor arising from synovial sarcoma: report of a case.
  • We report a case of metastatic breast tumor arising from a synovial sarcoma of the lower limb.
  • A 27-year-old Japanese woman was diagnosed to have synovial sarcoma 14 months prior to finding a mass in her left breast.
  • An excisional biopsy was performed and a metastatic synovial sarcoma to the breast was confirmed.
  • Eight months after the resection of the breast lesion, the patient developed local recurrences in both her knee and breast.
  • After the operation, the patient received adjuvant systemic chemotherapy.
  • To the best of our knowledge, this is only the second reported case of a solitary metastatic breast tumor arising from synovial sarcoma.
  • [MeSH-major] Breast Neoplasms / secondary. Knee. Neoplasm Recurrence, Local / therapy. Sarcoma, Synovial / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Lung Neoplasms / secondary. Mastectomy. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 1977 Oct;129(4):673-6 [409241.001]
  • [Cites] Radiol Clin North Am. 1982 Sep;20(3):561-8 [7111707.001]
  • [Cites] Radiology. 1982 Jul;144(2):309-12 [7089284.001]
  • [Cites] J Am Coll Surg. 1994 Jul;179(1):49-53 [8019724.001]
  • [Cites] Br J Cancer. 1965 Dec;19(4):738-43 [5862654.001]
  • [Cites] Urology. 1978 Jun;11(6):641-6 [675936.001]
  • [Cites] J Am Geriatr Soc. 1963 Sep;11:891-901 [14060379.001]
  • [Cites] AJR Am J Roentgenol. 1983 Oct;141(4):685-90 [6604418.001]
  • [Cites] Clin Orthop Relat Res. 1982 Apr;(164):257-60 [6279348.001]
  • [Cites] Cancer. 1972 Jun;29(6):1691-6 [4337956.001]
  • [Cites] Surgery. 1953 Mar;33(3):385-90 [13038624.001]
  • [Cites] Breast J. 2004 Jul-Aug;10(4):372 [15239802.001]
  • [Cites] Oncology. 1990;47(3):257-60 [2342767.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1981 Jul;89(4):251-6 [7315321.001]
  • [Cites] Clin Radiol. 1976 Oct;27(4):463-71 [187368.001]
  • [Cites] Cancer. 1950 Jan;3(1):74-85 [15405683.001]
  • [Cites] Br J Surg. 1959 Jul;47:54-8 [14441414.001]
  • [Cites] Surg Gynecol Obstet. 1974 Jan;138(1):26-8 [4809000.001]
  • (PMID = 17342363.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


23. Nishiyama N, Iwata T, Izumi N, Tsukioka T, Nagano K, Suehiro S: Aggressive repeat surgery for a recurrent synovial sarcoma in the pleura. Ann Thorac Cardiovasc Surg; 2009 Feb;15(1):46-9
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive repeat surgery for a recurrent synovial sarcoma in the pleura.
  • Pleural synovial sarcomas are an extremely rare disease entity, and only 21 surgical cases, including this one, have been reported.
  • We present a case of synovial sarcoma that underwent pneumonectomy for a recurrence of the disease.
  • A 31-year-old female, who in June 2005 had undergone surgical resection of a monophasic synovial sarcoma in the left pleural cavity combined with the affected left diaphragm, was admitted to our hospital in January 2007 and underwent chemotherapy with ifosfamide, pirarubicin, and methotrexate for a recurrent synovial sarcoma in the left pleural cavity.
  • The chest computed tomography revealed multiple tumors in the left pleura, and the tumors increased rapidly to occupy the left hemithorax.
  • No other recurrent sites were found, and she underwent tumor resection combined with the entire left lung in March 2007.
  • Pathological examination revealed dense proliferation of atypical spindle cells, the same findings as in the initial operation, and a diagnosis of synovial sarcoma was made.
  • External radiation therapy up to 60 Gray was given to the tumor remaining around the descending aorta.
  • Although optimal strategies for synovial sarcoma have yet to be established, aggressive repeat surgery could be considered in selected cases even when response to chemotherapy is insufficient and complete resection is difficult.
  • [MeSH-major] Neoplasm Recurrence, Local. Pleural Neoplasms / surgery. Pneumonectomy. Sarcoma, Synovial / surgery
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Radiotherapy, Adjuvant. Reoperation. Thoracotomy. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19262450.001).
  • [ISSN] 2186-1005
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


24. Boroumand N, Raja V, Jones DV, Haque AK: SYT-SSX2 variant of primary pulmonary synovial sarcoma with focal expression of CD117 (c-Kit) protein and a poor clinical outcome. Arch Pathol Lab Med; 2003 Apr;127(4):e201-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SYT-SSX2 variant of primary pulmonary synovial sarcoma with focal expression of CD117 (c-Kit) protein and a poor clinical outcome.
  • Pulmonary synovial sarcoma is a rare neoplasm recently recognized as a distinct entity and characterized by t(X;18) translocation and production of at least 2 fusion genes, SYT-SSX1 and SYT-SSX2.
  • We report a case of primary pulmonary synovial sarcoma with the SYT-SSX2 phenotype and a rapidly progressive downhill course.
  • Previous reports have suggested that the soft tissue synovial sarcomas with SYT-SSX2 phenotype have a favorable clinical outcome.
  • To the best of our knowledge, this is also the first report of CD117 (c-Kit) expression in a pulmonary synovial sarcoma.
  • After the patient underwent chemotherapy and brachytherapy, the specimen from a left pneumonectomy showed a large spindle cell tumor, which was reclassified as a synovial sarcoma based on the results of immunophenotyping and molecular genetic studies.
  • Differentiation between sarcoma and carcinosarcoma is crucial for implementing appropriate therapy.
  • Furthermore, if the tumor expresses c-Kit, it may respond to target-based therapy.
  • [MeSH-major] Genetic Variation / genetics. Lung Neoplasms / diagnosis. Lung Neoplasms / genetics. Oncogene Proteins, Fusion / genetics. Proto-Oncogene Proteins c-kit / biosynthesis. Sarcoma, Synovial / diagnosis. Sarcoma, Synovial / genetics

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12683902.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Oncogene Proteins, Fusion; 0 / SYT-SSX fusion protein; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


25. Niwa H, Masuda S, Kobayashi C, Oda Y: Pulmonary synovial sarcoma with polypoid endobronchial growth: a case report, immunohistochemical and cytogenetic study. Pathol Int; 2004 Aug;54(8):611-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary synovial sarcoma with polypoid endobronchial growth: a case report, immunohistochemical and cytogenetic study.
  • A rare case of primary pulmonary synovial sarcoma with polypoid endobronchial growth in a 42-year-old Japanese woman is described.
  • Left upper sleeve lobectomy was performed for the polypoid tumor measuring 2.5 cm in the left major bronchus and the patient was treated with adjuvant chemotherapy.
  • Recently, primary pulmonary synovial sarcoma is an increasingly recognized clinical entity; however, most of these tumors present as a parenchymal mass.
  • The present case is a unique example of primary synovial sarcoma of endobronchial polypoid type.
  • This case suggests that pulmonary synovial sarcoma might originate from bronchial submucosal stromal tissue.
  • [MeSH-major] Bronchi / pathology. Lung Neoplasms / pathology. Polyps / pathology. Sarcoma, Synovial / secondary
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Lung / pathology. Lung / surgery. Neoplasm Proteins / genetics. Neoplasm Recurrence, Local. Proteins / genetics. Proto-Oncogene Proteins. RNA, Messenger / metabolism. RNA, Neoplasm / analysis. Repressor Proteins / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15260852.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Repressor Proteins; 0 / SS18 protein, human; 164289-47-8 / synovial sarcoma X breakpoint proteins
  •  go-up   go-down


26. Daw NC, Kaste SC, Hill DA, Kun LE, Pratt CB: Metastatic osteosarcoma to the liver after treatment for synovial sarcoma: a case report. Pediatr Hematol Oncol; 2001 Mar;18(2):123-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic osteosarcoma to the liver after treatment for synovial sarcoma: a case report.
  • Hepatic metastasis at the time of diagnosis is extremely rare.
  • A 14-year-old boy with synovial sarcoma of the left popliteal fossa was treated with surgical resection, radiotherapy for microscopic residual disease, and 1 year of chemotherapy (vincristine, cyclophosphamide, dactinomycin, and doxorubicin).
  • Approximately 10 years after the initial diagnosis, a secondary osteosarcoma developed in the left proximal tibia.
  • Computed tomography at presentation showed bilateral pulmonary metastases and large ossified nodules in the liver that demonstrated abnormal avidity on 99mTc MDP bone scan indicating hepatic metastasis.
  • Despite chemotherapy (cisplatin, ifosfamide, high-dose methotrexate, and dacarbazine), the patient died of progressive disease 4 months after the diagnosis of the second cancer.
  • Hepatic metastasis was found at the time of diagnosis of a secondary osteosarcoma and manifested as ossified nodules.
  • The risk of radiation-induced osteosarcoma should always be considered in decisions about treatment for soft-tissue sarcoma.
  • [MeSH-major] Liver Neoplasms / secondary. Osteosarcoma / pathology. Sarcoma, Synovial / pathology. Sarcoma, Synovial / radiotherapy
  • [MeSH-minor] Adolescent. Fatal Outcome. Humans. Lung Neoplasms / radionuclide imaging. Lung Neoplasms / secondary. Male. Neoplasms, Radiation-Induced / pathology. Neoplasms, Second Primary / etiology. Neoplasms, Second Primary / pathology. Ossification, Heterotopic / etiology. Ossification, Heterotopic / radionuclide imaging. Radiopharmaceuticals. Radiotherapy / adverse effects. Technetium Tc 99m Medronate. Tomography, Emission-Computed / standards

  • Genetic Alliance. consumer health - Osteosarcoma.
  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11255730.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / CA-23099
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


27. Minig L, Farnetano G, Peiretti M, Roviglione G, Zanagnolo V, Pelosi G, Landoni F: Poorly differentiated synovial sarcoma of the vagina: a case report and a clinical literature review. Ecancermedicalscience; 2008;2:99

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poorly differentiated synovial sarcoma of the vagina: a case report and a clinical literature review.
  • Synovial sarcomas (SS) account for 5-10% of soft-tissue sarcomas and typically arise in the para-articular regions of adolescents and young adults.
  • The patient, prior to the radical surgery, received neoadjuvant chemotherapy (ifosfamide and epirubicin) for three cycles.
  • She underwent post-operative external radiotherapy and brachytherapy (50 Gy) due to close margins (<1 mm) in the pathologic specimen.
  • She relapsed 11 and 16 months later with lung metastases, which, both times, were successfully removed by surgical resection.
  • In summary, in the presence of unfavourable prognostic factors, neoadjuvant chemotherapy could be the primary approach to reduce the tumour size and the risk of distant micro-metastases allowing a less aggressive radical surgery if the tumour is located in a non-extremity site.
  • In fact, in our patient we obtained a complete clinical control in the pelvis, avoiding pelvic exenteration with neoadjuvant chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22275979.001).
  • [ISSN] 1754-6605
  • [Journal-full-title] Ecancermedicalscience
  • [ISO-abbreviation] Ecancermedicalscience
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3234049
  •  go-up   go-down


28. Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I: Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer; 2008 Apr 1;112(7):1585-91
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
  • BACKGROUND: The efficacy of palliative chemotherapy was investigated in a large group of patients with advanced soft-tissue sarcomas (STS) treated on routine palliative protocols.
  • METHODS: Patients with STS who had first-line chemotherapy for advanced and/or metastatic disease between 1991 and 2005 were identified from the Royal Marsden Hospital's sarcoma database.
  • Patients with Ewing sarcoma, rhabdomyosarcoma, desmoplastic small round cell tumor, and gastrointestinal stromal tumors were excluded from the study.
  • The median age was 49 years and the majority (83%) received chemotherapy for metastatic disease.
  • The most common histologic subtypes were leiomyosarcoma (35%) synovial sarcoma (13%), liposarcoma (10%), and malignant fibrous histiocytoma (10%).
  • In all, 61% received single-agent chemotherapy, usually doxorubicin.
  • An objective response was reported in 33% of patients (53% in those with synovial sarcoma); 22% had stable disease and 45% derived 'clinical benefit' (objective responses + stable disease for >or= 6 months).
  • In multivariate analysis, age <40 years, liposarcoma, and synovial histology were found to be positive, and bone involvement to be negative, independent prognostic factors.
  • Patients treated with combination chemotherapy experienced longer OS than those treated with a single agent.
  • CONCLUSIONS: Palliative chemotherapy may be beneficial in approximately half of patients with advanced STS.
  • Synovial sarcoma and liposarcoma subtypes have a better prognosis.
  • [MeSH-major] Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Palliative Care. Prognosis. Prospective Studies. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18278813.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Minchom A, Jones RL, Fisher C, Al-Muderis O, Ashley S, Scurr M, Karavasilis V, Judson IR: Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcoma. Sarcoma; 2010;2010:264360

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcoma.
  • Background. This paper aimed to assess the utility of second-line chemotherapy in patients with advanced soft-tissue sarcoma.
  • Patients with gastrointestinal stromal tumours, small round cell tumours, and Ewing's sarcoma were excluded.
  • Results. Three hundred and seventy-nine patients received second-line chemotherapy.
  • On multivariate analysis, pathological subtype, absence of lung metastases, and the use of combination chemotherapy were independent predictors of disease control.
  • Twenty-eight (16.1%) patients who failed to respond to first-line therapy achieved disease control.
  • On multivariate analysis, synovial histology and absence of lung metastases were associated with improved survival.
  • Conclusion. Second-line chemotherapy can provide clinical benefit in over 20% of soft-tissue sarcoma patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3126-32 [19451427.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):543-9 [11872347.001]
  • [Cites] Cancer Treat Rev. 2008 Jun;34(4):339-47 [18313854.001]
  • [Cites] Cancer. 2008 Apr 1;112(7):1585-91 [18278813.001]
  • [Cites] Expert Opin Ther Targets. 2008 Feb;12(2):197-207 [18208368.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):463-7 [18202421.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3144-50 [17634494.001]
  • [Cites] Eur J Cancer. 2005 Dec;41(18):2853-60 [16289617.001]
  • [Cites] Oncologist. 2005 Nov-Dec;10(10):833-41 [16314294.001]
  • [Cites] N Engl J Med. 2005 Aug 18;353(7):701-11 [16107623.001]
  • [Cites] Drugs. 2005;65(2):167-78 [15631540.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):150-7 [10458228.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(1):64-9 [12504660.001]
  • [Cites] Lancet Oncol. 2000 Oct;1:75-85 [11905672.001]
  • [Cites] Curr Oncol Rep. 2008 Jul;10(4):329-37 [18778559.001]
  • (PMID = 20508840.001).
  • [ISSN] 1369-1643
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2874927
  •  go-up   go-down


30. Li EX, Zhang YT, Shang JT, Xu Z, Geng Y, Li SM, Shi F, Wu YY: [Effect of modified MAID regimen for patients with advanced soft tissue sarcoma]. Ai Zheng; 2006 Aug;25(8):1048-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of modified MAID regimen for patients with advanced soft tissue sarcoma].
  • BACKGROUND & OBJECTIVES: Clinical study suggests that 72-hour continuous infusion (CIV) of MAID regimen is more effective and achieves longer time of no progression than ADR-based two-drug regimen in advanced soft tissue sarcoma (ASTS) treatment, but has no improvement on the long-term survival.
  • Because of the severe grade 3/4 toxicities as well as treatment-related deaths, the regimen has not been widely applied in ASTS.
  • This study was to investigate the efficacy and toxicity of the modified MAID regimen in ASTS treatment.
  • All enrolled patients received chemotherapy (IFO 2,000 mg .
  • The therapy was repeated every 3 weeks for at least 2 cycles before evaluating the effects and toxicities.
  • Life table was used to calculate long-term survival rates and time to progression.
  • RESULTS: Fifty-four cases of evaluable patients had completed at least 2 cycles of modified MAID chemotherapy.
  • There were no other toxicities, such as hepatic and renal toxicities; no central nervous system toxicity and treatment-related deaths.
  • During 2 year follow-up, time to progression was 7 months, 1- and 2- year survival rates were 61.11% and 36.36%, respectively.
  • CONCLUSIONS: Modified MAID regimen simplifies the application of treatment procedure compared with original regimen, which three drugs have to be CIV simultaneously.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fibrosarcoma / drug therapy. Rhabdomyosarcoma / drug therapy. Sarcoma, Synovial / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Infusions, Intravenous. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Nausea / chemically induced. Neoplasm Staging. Neutropenia / chemically induced. Remission Induction. Survival Rate. Thrombocytopenia / chemically induced. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965692.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; D58G680W0G / pirarubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


31. Etienne-Mastroianni B, Falchero L, Chalabreysse L, Loire R, Ranchère D, Souquet PJ, Cordier JF: Primary sarcomas of the lung: a clinicopathologic study of 12 cases. Lung Cancer; 2002 Dec;38(3):283-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sarcomas of the lung: a clinicopathologic study of 12 cases.
  • PURPOSE: To study patients with primary sarcomas of the lung diagnosed in our pathology department in order to define their clinical characteristics, treatment, and prognosis.
  • The histologic diagnoses confirmed in all cases by detailed immunohistochemical study were leiomyosarcoma (7), monophasic synovial sarcoma (2), one case each of malignant peripheral nerve sheath tumor (MPNST), epithelioid sarcoma, and malignant fibrous histiocytoma.
  • Four patients received chemotherapy and two patients had radiation therapy postoperatively.
  • CONCLUSIONS: Primary sarcomas of the lung are a rare and aggressive malignancy.
  • Treatment and prognosis do not differ from other soft tissue sarcomas.
  • [MeSH-major] Lung Neoplasms / pathology. Sarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12445750.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


32. Dursunoğlu N, Kiter G, Oztürk E, Tunç P, Colakoğlu N, Değirmencioğlu S, Yaren A: An old woman with weight loss and chest pain. Tuberk Toraks; 2010;58(1):85-8
MedlinePlus Health Information. consumer health - Weight Control.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pulmonary sarcomas constitute only 0.1-0.5% of all primary lung malignancies.
  • These tumors may derive from the lung parenchyma, bronchial tree or pulmonary arteries.
  • The most important entity in the differential diagnosis is metastatic synovial sarcoma.
  • A chest computerised tomography showed enlarged mediastinal lymph nodes were observed, as well as a left-sided pleural effusion.
  • Left sided thoracoscopy was performed under local anesthesia, total collapse of left lung and multiple pleural nodules were observed on the visceral pleura multiple biopsies were obtained from those nodules.
  • Pathologic examinations revealed "synovial sarcoma".
  • As skeleton single photon emission tomography was unremarkable, primary pleuropulmonary synovial sarcoma was decided as diagnosis and chemotherapy was planned for the patient.
  • Primary pleuropulmonary synovial sarcoma is a rare neoplasm of lung and pleura but it is rare entity.
  • [MeSH-major] Chest Pain / diagnosis. Lung Neoplasms / diagnosis. Sarcoma, Synovial / diagnosis. Weight Loss

  • MedlinePlus Health Information. consumer health - Chest Pain.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20517734.001).
  • [ISSN] 0494-1373
  • [Journal-full-title] Tüberküloz ve toraks
  • [ISO-abbreviation] Tuberk Toraks
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


33. Zong XY, Shi YQ: [Experience and discussion on treatment of high-grade soft tissue sarcomas of crura in youth]. Zhonghua Wai Ke Za Zhi; 2004 Oct 22;42(20):1247-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experience and discussion on treatment of high-grade soft tissue sarcomas of crura in youth].
  • OBJECTIVE: To summarize the experience and investigate better method on treatment of high-grade soft tissue sarcomas of crura in youth.
  • METHODS: Six young cases suffered from high-grade soft tissue sarcomas of crura were treated by interpolatory chemotherapy using vindesine 4mg or vincristine 2 mg combined with cisplatin 40 - 60 mg and 4'-Epidoxorubicin (4'-epi-ADM) 50 - 80 mg.
  • The pathological type of these 6 cases were: 1 small round cell tumor from soft tissue, one rabdomyosarcoma, one alveoliar soft part sarcoma, one synovial sarcoma, one primitive neuroectodermal tumor and one without classification.
  • All cases received interpolatory chemotherapy twice.
  • Before their receiving interpolatory chemotherapy they had no tumor metastases.
  • One patient's tumor disappeared after interpolatory chemotherapy and she received no further therapy.
  • The other 5 cases received operations and one of them received additional pre-operational radiotherapy using Co(60) and pre-operational systemic chemotherapy using ifosfamide and dacarbazine.
  • RESULTS: The tumors dwindled in size of 1 - 8 cm after interpolatory chemotherapy.
  • After interpolatory chemotherapy, all patients suffered from edema and ache of crura.
  • A lung metastasis was found in 1 patient by CT 2 months after surgery, then he was in hospital and treated by chemotherapy.
  • CONCLUSIONS: For treatment of high-grade soft tissue sarcomas of crura which are difficult to resect in youth, interpolatory chemotherapy is a good choice.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Extremities. Sarcoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15598374.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


34. Turcotte RE, Ferrone M, Isler MH, Wong C: Outcomes in patients with popliteal sarcomas. Can J Surg; 2009 Feb;52(1):51-5
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Soft-tissue sarcoma involving the popliteal fossa remains challenging because it is difficult to achieve wide margins with limb salvage in this location.
  • Adjuvant therapy is frequently necessary, and limb function can be adversely affected.
  • Frequent histologic diagnoses were liposarcoma (n = 6), synovial sarcoma (n = 4) and leiomyosarcoma (n = 3).
  • Treatment consisted of limb salvage in 15 patients and amputation in 3.
  • Fourteen patients had radiotherapy, 4 had chemotherapy, and 3 needed partial sciatic nerve resection.
  • Of the patients undergoing limb-salvaging procedures, 1 experienced local recurrences after limb salvage (7%), and 5 experienced lung metastases (20%).
  • [MeSH-major] Knee. Outcome Assessment (Health Care). Sarcoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amputation / statistics & numerical data. Chemotherapy, Adjuvant. Databases, Factual. Female. Humans. Limb Salvage. Lung Neoplasms / secondary. Male. Middle Aged. Prospective Studies. Radiotherapy, Adjuvant. Retrospective Studies. Sciatic Nerve / surgery. Surgical Wound Dehiscence / etiology. Surgical Wound Infection / etiology. Thrombophlebitis / etiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 2000 Apr;73(4):206-11 [10797333.001]
  • [Cites] Eur J Surg Oncol. 2007 May;33(4):512-7 [17174515.001]
  • [Cites] Acta Orthop Scand. 2001 Apr;72(2):160-6 [11372947.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2235-41 [12103287.001]
  • [Cites] Ann Surg Oncol. 2004 May;11(5):476-82 [15078635.001]
  • [Cites] Ann Surg. 1968 Jul;168(1):47-53 [4299767.001]
  • [Cites] J Bone Joint Surg Am. 1980 Sep;62(6):1027-30 [7000786.001]
  • [Cites] Cancer. 1981 Mar 1;47(5):1005-22 [7226034.001]
  • [Cites] Cancer. 1986 Apr 15;57(8):1632-9 [3948134.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):9-24 [3456859.001]
  • [Cites] Acta Orthop Scand. 1987 Oct;58(5):516-22 [3425281.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):817-23 [3338039.001]
  • [Cites] Cancer. 1989 Apr 1;63(7):1437-51 [2646010.001]
  • [Cites] J Bone Joint Surg Am. 1989 Mar;71(3):370-5 [2925710.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):899-906 [2211257.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1493-9 [1938558.001]
  • [Cites] J Surg Oncol. 1993 Apr;52(4):223-30 [8468983.001]
  • [Cites] Clin Orthop Relat Res. 1993 Apr;(289):19-31 [8472413.001]
  • [Cites] Clin Orthop Relat Res. 1993 Apr;(289):73-80 [8472434.001]
  • [Cites] Eur J Cancer. 1994;30A(6):746-51 [7917531.001]
  • [Cites] Cancer. 1995 Oct 15;76(8):1398-405 [8620414.001]
  • [Cites] Curr Probl Surg. 1996 Oct;33(10):817-72 [8885853.001]
  • [Cites] Qual Life Res. 1996 Oct;5(5):508-16 [8973131.001]
  • [Cites] Clin Orthop Relat Res. 1999 Jan;(358):90-100 [9973980.001]
  • [Cites] Radiother Oncol. 2005 Apr;75(1):48-53 [15948265.001]
  • [Cites] Clin Orthop Relat Res. 2007 Feb;455:225-33 [16957647.001]
  • [Cites] Surg Oncol. 1999 Dec;8(4):211-4 [11128835.001]
  • (PMID = 19234652.001).
  • [ISSN] 1488-2310
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2637647
  •  go-up   go-down


35. Zhang PJ, Brooks JS, Goldblum JR, Yoder B, Seethala R, Pawel B, Gorman JH, Gorman RC, Huang JH, Acker M, Narula N: Primary cardiac sarcomas: a clinicopathologic analysis of a series with follow-up information in 17 patients and emphasis on long-term survival. Hum Pathol; 2008 Sep;39(9):1385-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although cardiac sarcomas are rare in comparison to their soft tissue counterparts, they are the second most common type of primary cardiac neoplasm.
  • There were 6 angiosarcomas, 6 myxofibrosarcomas, 3 malignant peripheral nerve sheath tumors, 3 leiomyosarcomas, 2 synovial sarcomas, 1 epithelioid hemangioendothelioma, 1 chondrosarcoma, 1 osteosarcoma, and 4 poorly differentiated sarcomas.
  • Six high-grade and 1 low-grade tumors were also treated with adjuvant chemotherapy and/or radiation.
  • Tumor grade appeared to be prognostically important in cardiac sarcoma.
  • [MeSH-major] Heart Neoplasms / pathology. Sarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2000 Jun;69(6):1949-51 [10892961.001]
  • [Cites] Z Kardiol. 2002 Apr;91(4):352-6 [12063709.001]
  • [Cites] J Heart Lung Transplant. 2002 Oct;21(10):1135-9 [12398881.001]
  • [Cites] Rev Esp Cardiol. 2003 Apr;56(4):408-11 [12689577.001]
  • [Cites] Chest. 2003 May;123(5):1766-8 [12740300.001]
  • [Cites] Thorac Cardiovasc Surg. 2004 Apr;52(2):77-81 [15103579.001]
  • [Cites] Ann Surg. 1980 Feb;191(2):127-38 [7362282.001]
  • [Cites] Hum Pathol. 1982 Jul;13(7):640-5 [7084941.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):530-41 [6692258.001]
  • [Cites] Arch Pathol Lab Med. 1985 Oct;109(10):943-5 [3840005.001]
  • [Cites] Chest. 1987 Jul;92(1):177-9 [3595230.001]
  • [Cites] Chest. 1987 Nov;92(5):860-2 [3665601.001]
  • [Cites] Thorac Cardiovasc Surg. 1990 Aug;38 Suppl 2:183-91 [2237900.001]
  • [Cites] Thorac Cardiovasc Surg. 1990 Aug;38 Suppl 2:192-5 [2237901.001]
  • [Cites] Ann Thorac Surg. 1991 Jun;51(6):906-10 [2039319.001]
  • [Cites] Ann Thorac Surg. 1991 Jun;51(6):999-1001 [2039335.001]
  • [Cites] Ann Thorac Surg. 1991 Oct;52(4):886-95 [1929651.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):387-95 [1728367.001]
  • [Cites] Am Heart J. 1992 Jan;123(1):232-4 [1729836.001]
  • [Cites] Aust N Z J Med. 1991 Dec;21(6):881-3 [1818549.001]
  • [Cites] Scand J Thorac Cardiovasc Surg. 1992;26(3):233-6 [1287840.001]
  • [Cites] J Cardiovasc Surg (Torino). 1993 Dec;34(6):529-33 [8300722.001]
  • [Cites] Semin Surg Oncol. 1994 Sep-Oct;10(5):374-82 [7997732.001]
  • [Cites] J Heart Lung Transplant. 1995 Mar-Apr;14(2):382-6 [7779860.001]
  • [Cites] Hum Mol Genet. 1995 Jun;4(6):1097-9 [7655467.001]
  • [Cites] Histopathology. 1997 Apr;30(4):349-52 [9147083.001]
  • [Cites] Jpn Circ J. 1997 Sep;61(9):795-7 [9293411.001]
  • [Cites] Ann Diagn Pathol. 1998 Jun;2(3):167-72 [9845736.001]
  • [Cites] Br J Cancer. 1998 Dec;78(12):1624-8 [9862574.001]
  • [Cites] J Surg Oncol. 1999 Mar;70(3):194-8 [10102352.001]
  • [Cites] Histopathology. 1999 Apr;34(4):295-304 [10231396.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Jun;29(6):925-32 [16675225.001]
  • [Cites] J Thorac Oncol. 2006 Feb;1(2):188-9 [17409853.001]
  • [Cites] Gen Thorac Cardiovasc Surg. 2007 Jan;55(1):19-22 [17444167.001]
  • [Cites] Oncologist. 2007 Sep;12(9):1134-42 [17914083.001]
  • (PMID = 18602663.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL063954
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS522251; NLM/ PMC4081532
  •  go-up   go-down


36. Karnak I, Emin Senocak M, Kutluk T, Tanyel FC, Büyükpamukçu N: Pulmonary metastases in children: an analysis of surgical spectrum. Eur J Pediatr Surg; 2002 Jun;12(3):151-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pulmonary surgery is frequently used for the treatment of metastasis or nodules in children with various types of malignancies.
  • The primaries were osteosarcoma (n = 2), synovial sarcoma (n = 1), fibrosarcoma (n = 1), Ewing's sarcoma (n = 2), mesenchymal chondrosarcoma (n = 1), Wilms' tumour (n = 4), clear-cell sarcoma (n = 1), Hodgkin lymphoma (n = 3), hepatoblastoma (n = 1), hepatocellular carcinoma (n = 1) and haemangioendotheliosarcoma (n = 1).
  • Pulmonary metastases were encountered either at the time of initial diagnosis (22 %) or occurred within 6 months to 5 years.
  • They were frequently nodular (94 %), unilateral (94 %) and located in the right lung (70 %).
  • The nodules contained tumour cells in most cases (n = 14) (78 %), mature nephrogenic elements (6 %) and no tumour tissue (16 %) in the remaining cases.
  • However, synovial sarcoma was encountered in metastasis in one case with fibrosarcoma primary.
  • Therefore combined therapies such as chemotherapy and/or radiotherapy should be continued in the postoperative period.
  • [MeSH-major] Lung Neoplasms / secondary. Lung Neoplasms / surgery
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Pneumonectomy. Retrospective Studies. Thoracotomy. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12101495.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


37. Zhao J, Wang MZ, Li LY, Zhang L, Zhong W: [Clinical features of pulmonary malignancies in patients younger than 30 years of age]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Apr;32(2):174-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mean time from the onset of disease to confirmed diagnosis was (5.98+/-8.95) months.
  • The proportions of advanced-stage patients (stage III B and IV) and moderate to poor-differentiated tumor accounted for 59.26% (16/27) and 77.8% (14/18), respectively in 27 patients with non-small cell lung cancer.
  • The proportion of tumors in limited stage was 72.73% in 11 patients with small cell lung cancer, and most patients (54.55) were not sensitive to conventional chemotherapy.
  • In 6 patients with carcinoid, 4 patients were central and the other 2 patients were peripheral, and all of them presented as Cushing syndrome; CgA, AE1/AE3, Syn, and NSE were positive in immunohistochemical staining; and surgical operation was the main treatment for them.
  • In 6 patients with carcinomas of salivary gland type, all cases were central; no lymph nodes metastasis was found in the postoperative specimen; and surgical operation was also the main treatment for these patients.
  • Multiple nodules in bilateral lungs were presented in 2 patients with anaplastic large cell lymphomas, in which CD30 was positive in tumor cells; chemotherapy was the main therapy for these two patients.
  • In one patient with synovial sarcoma, the tumor was giant and highly malignant and invasive; it was divided into many cavities filled with bloody fluid and white cheese-like substances; immunohistochemical analysis showed positive vimentin and AE1/AE3.
  • The treatment strategy should be based on the specific conditions of each patient.
  • [MeSH-major] Lung Neoplasms

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450548.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


38. Emori M, Naka N, Hamada K, Tomita Y, Takami H, Araki N: Soft-tissue sarcomas in the inguinal region may present as deep vein thrombosis. Ann Vasc Surg; 2010 Oct;24(7):951.e7-951.e11
MedlinePlus Health Information. consumer health - Vascular Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft-tissue sarcomas in the inguinal region may present as deep vein thrombosis.
  • Soft-tissue sarcomas arising in the inguinal region may encompass or be adjacent to femoral vessels and result in venous obstruction, mimicking symptoms of DVT.
  • We present two cases of soft-tissue sarcomas in the inguinal region that were initially misdiagnosed as spontaneous DVT and administered unnecessary long-term anticoagulation therapy.
  • [MeSH-major] Diagnostic Errors. Leiomyosarcoma / diagnosis. Lower Extremity / blood supply. Sarcoma, Synovial / diagnosis. Soft Tissue Neoplasms / diagnosis. Vascular Diseases / etiology. Venous Thrombosis / diagnosis
  • [MeSH-minor] Adult. Anticoagulants / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Blood Vessel Prosthesis Implantation. Chemotherapy, Adjuvant. Constriction, Pathologic. Edema / etiology. Fatal Outcome. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Male. Neoadjuvant Therapy. Time Factors. Treatment Outcome. Ultrasonography, Doppler, Duplex. Unnecessary Procedures. Veins / pathology

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Annals of Vascular Surgery Inc. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20471794.001).
  • [ISSN] 1615-5947
  • [Journal-full-title] Annals of vascular surgery
  • [ISO-abbreviation] Ann Vasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants
  •  go-up   go-down


39. Xu J, Sun H, Xiao Y: [Application of medial head gastrocnemius muscle flap to limb-salvage operation of proximal tibial malignant tumor]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2007 Apr;21(4):352-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among them, there were 4 patients with osteosarcoma, 6 with malignant fibrous histocytoma, 1 with malignant giant cell tumor, 1 with synovial sarcoma, and 1 with Ewing's sarcoma.
  • One or two cycles of neoadjuvant chemotherapy were used to each of the patients before operation.
  • All of the patients underwent the medial head of the gastrocnemius muscle flap transposition to reconstruct the soft tissues after resection of the tumors and reconstruction of the bone defect by prothesis or bone-graft or the two methods combined.
  • The patient with Ewing's sarcoma had a local tumor recurrence 18 months after operation; though treated with the focal cleaning and the bone cement filling, the patient still developed lung metastasis of the tumor 26 months after operation.
  • CONCLUSION: The flap transposition of the medial head of the gastrocnemius muscle can reconstruct the soft tissue defect, decrease the local complication rate and improve the clinical outcome of the limb salvage for the proximal tibia malignant tumor.
  • [MeSH-major] Bone Neoplasms / surgery. Limb Salvage / methods. Osteosarcoma / surgery. Soft Tissue Injuries / surgery. Surgical Flaps / blood supply. Tibia
  • [MeSH-minor] Adolescent. Adult. Arthroplasty, Replacement, Knee. Bone Transplantation / methods. Female. Follow-Up Studies. Humans. Male. Middle Aged. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17546876.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


40. Bhargava P, Marshall JL, Dahut W, Rizvi N, Trocky N, Williams JI, Hait H, Song S, Holroyd KJ, Hawkins MJ: A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers. Clin Cancer Res; 2001 Dec;7(12):3912-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three or more patients were treated at each dose, of which at least one patient started treatment de novo at that dose.
  • Three patients did not experience hepatotoxicity when first treated at 384 mg/m(2)/day but developed DLT at the same dose when de-escalated from 538 mg/m(2)/day.
  • Transient tumor responses were observed in a patient with synovial cell sarcoma and a patient with breast carcinoma with cutaneous metastases.
  • On the basis of preclinical evidence of synergy with cytotoxic agents and demonstration of human safety from this trial, additional clinical trials have been initiated with squalamine in combination with chemotherapy for patients with late stage lung cancer and ovarian cancer.
  • [MeSH-major] Anticarcinogenic Agents / pharmacokinetics. Anticarcinogenic Agents / toxicity. Cholestanols / pharmacokinetics. Cholestanols / toxicity. Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Angiogenesis Inhibitors / pharmacokinetics. Angiogenesis Inhibitors / toxicity. Dose-Response Relationship, Drug. Fatigue / chemically induced. Female. Humans. Liver / drug effects. Liver / pathology. Male. Metabolic Clearance Rate. Middle Aged

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11751482.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Anticarcinogenic Agents; 0 / Cholestanols; F8PO54Z4V7 / squalamine
  •  go-up   go-down


41. Basso U, Brunello A, Bertuzzi A, Santoro A: Sorafenib is active on lung metastases from synovial sarcoma. Ann Oncol; 2009 Feb;20(2):386-7
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sorafenib is active on lung metastases from synovial sarcoma.

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19211500.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


42. Block KI, Gyllenhaal C, Newman RA: Response to 'Probable hepatotoxicity related to Nerium oleander extract in a patient with metastatic synovial sarcoma of the knee'. J Altern Complement Med; 2009 Dec;15(12):1269; author reply 1271
MedlinePlus Health Information. consumer health - Drug Reactions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to 'Probable hepatotoxicity related to Nerium oleander extract in a patient with metastatic synovial sarcoma of the knee'.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Drug-Induced Liver Injury / etiology. Nerium / toxicity. Plant Extracts / adverse effects. Plant Poisoning. Sarcoma, Synovial / drug therapy
  • [MeSH-minor] Adult. Animals. Female. Humans. Knee Joint. Lung Neoplasms / secondary

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19958106.001).
  • [ISSN] 1557-7708
  • [Journal-full-title] Journal of alternative and complementary medicine (New York, N.Y.)
  • [ISO-abbreviation] J Altern Complement Med
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Plant Extracts
  •  go-up   go-down






Advertisement